Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions. 

Join us as we discuss the importance of early identification of MASH (metabolic&nbsp;dysfunction-associated steatohepatitis), including how to accurately identify and select patients who are at risk for clinically significant fibrosis. We will also discuss clinical trial data for patients with MASH and stage 2 or 3 fibrosis.<br />
<br />
Industry Supporter:&nbsp;Novo Nordisk, Inc.

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions.

The following poster categories will be in the Poster Hall:
<ul>
<li>MASLD/MASH - Experimental: Basic</li>
<li>Hepatitis B</li>
<li>Hepatitis C</li>
<li>MASLD/MASH - Experimental: Clinical</li>
<li>Alcohol-Associated Liver Diseases: Clinical and Experimental</li>
</ul>

Join us for a poster highlight of the top abstracts from the Clinical Practice SIG.&nbsp;<br />
&nbsp;

Presenters explore new practice paradigms for optimizing liver tarnsplant acccess and examine effective strategies for dissemination of knowledge regarding the benefit of living donor liver transplant (LDLT) through directed, nondirected, and paired donation. Other topics include the role of machine perfusion in improving transplant access, outreach hepatology and transplant clinics, telehepatology, and the role of minimally-invasive surgical techniques in the growth of LDLT programs.

Presenters focus on empowering patients to effectively navigate the health care system. Topics include debunking common myths, utilizing practical tools, and understanding the differences between alternative, complementary, and integrative medicine.

Panelists highlight the perspectives of providers and people living with hepatitis B regarding strategies to assess and address patient-reported outcomes, and cultivate shared decision-making that is informed by scientific evidence, provider expertise, and patient preferences. The diverse panel includes representatives of nonprofit organizations, health systems, academic institutions, and patient advocacy groups. A question-and-answer period follows speaker presentations.

CDC's Division of Viral Hepatitis Director Carolyn Wester will discuss the on-going work at DVH and the division's role in the White House Hepatitis C Elimination plan.

This session will highlight evolving approaches to second-line treatment in Primary Biliary Cholangitis (PBC) through a case-based discussion. It will provide practical insights and foster a dynamic exchange between leading hepatologists.<br />
<br />
Industry Supporter:&nbsp;Ipsen